PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company 15th November 2017
PhoreMost Ltd and University of Cambridge collaborate to identify innovative drug targets for neurodegenerative disease 12th October 2016
PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets in Cancer, Immunotherapy and Aging 10th March 2016